FOLD

Amicus Therapeutics (FOLD) is trading as a pure merger arbitrage play, tightly pinned at $14.46 against BioMarin's definitive $14.50 all-cash acquisition offer. This M&A catalyst perfectly explains the exceptionally low 1.9% annualized volatility, flat 1-day price action, and the presence of 'Quiet Storm' and 'Steady Climb' technical signals as the stock slowly converges to the deal price. While the broader market is in a highly favorable RISK_ON regime driven by geopolitical tailwinds, FOLD's conviction level and price discovery are entirely insulated from macro beta, relying strictly on the successful completion of the $4.8 billion BioMarin buyout.